Piperacillin‐tazobactam dosing in anuric acute kidney injury patients receiving continuous renal replacement therapy
Seminars in Dialysis · 2023
DOI: 10.1111/sdi.13148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Seminars in Dialysis, 2023. Verfasst von Dhakrit Rungkitwattanakul und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Administrative Pharmacy Sciences, College of Pharmacy, Howard University, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Continuous Renal Replacement Therapy, Acute Kidney Injury. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Siam University.
Abstract (Originalsprache)
Introduction
To determine appropriate dosing of piperacillin‐tazobactam in critically ill patients receiving continuous renal replacement therapy (CRRT).
Methods
The databases of PubMed, Embase, and ScienceDirect were searched. We used the Medical Subject Headings of “piperacillin‐tazobactam,” “CRRT,” and “pharmacokinetics” or related terms or synonym to identify the studies for reviews. A one‐compartment pharmacokinetic model was conducted to predict piperacillin levels for the initial 48 h of therapy. The pharmacodynamic target was 50% of free drug level above the minimum inhibitory concentration (MIC) and 4 times of the MIC. The dose that achieved at least 90% of the probability of target attainment was defined as an optimal dose.
Results
Our simulation study reveals that the dosing regimen of piperacillin‐tazobactam 12 g/day is appropriate for treating Pseudomonal infection with KDIGO recommended effluent rate of 25–35 mL/kg/h. The MIC values of each setting were an important factor to design piperacillin‐tazobactam dosing regimens.
Conclusion
The Monte Carlo simulation can be a useful tool to evaluate drug dosing in critically ill acute kidney injury patients receiving CRRT when limited pharmacokinetic data are a concern. Clinical validation of these results is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Administrative Pharmacy Sciences, College of Pharmacy, Howard University, Washington, District of Columbia, USA.
- Faculty of Pharmacy, Siam University, Bangkok, Thailand.
- Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand.
- Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
ORCID-Profile: Dhakrit Rungkitwattanakul, Nattachai Srisawat, Weerachai Chaijamorn
Förderung
- Siam University
Zitieren
APA
Rungkitwattanakul, D., Charoensareerat, T., Chaichoke, E., Rakamthong, T., Srisang, P., Pattharachayakul, S., Srisawat, N., & Chaijamorn, W. (2023). Piperacillin‐tazobactam dosing in anuric acute kidney injury patients receiving continuous renal replacement therapy. Seminars in Dialysis. https://doi.org/10.1111/sdi.13148
Vancouver
Rungkitwattanakul D, Charoensareerat T, Chaichoke E, Rakamthong T, Srisang P, Pattharachayakul S, et al. Piperacillin‐tazobactam dosing in anuric acute kidney injury patients receiving continuous renal replacement therapy. Seminars in Dialysis. 2023. doi:10.1111/sdi.13148
BibTeX
@article{Rungkitwattanakul2023,
author = {Rungkitwattanakul, Dhakrit and Charoensareerat, Taniya and Chaichoke, Ekanong and Rakamthong, Thanakorn and Srisang, Pitchaya and Pattharachayakul, Sutthiporn and Srisawat, Nattachai and Chaijamorn, Weerachai},
title = {Piperacillin‐tazobactam dosing in anuric acute kidney injury patients receiving continuous renal replacement therapy},
journal = {Seminars in Dialysis},
year = {2023},
doi = {10.1111/sdi.13148}
}
EUVIMED